NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Mimedx Group, Inc. MDXG
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$418.6M
▲ 20.0% vs FY2024
EPS · FY25
$0.32
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
21.6%
Net margin · FY25
11.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 418.6M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
12 cents of every revenue dollar became profit this year.
Per share
USD 0.32
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
21.6%
Return on equity, FY2025
ROE
Operating margin15.3%
Net margin11.6%
Return on assets16.0%
Each USD of equity produced 22 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 0.00
Share of profit0.0%
Consecutive raises—
Growth
+11.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+16.1%
+11.0%
+8.4%
+51.9%
Net income
+5.1%
EPS, diluted
+2.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.15B
Shares outstanding, FY2025
Change, 5 years+33.5%
Change, 10 years+37.9%
The share count grew 34% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 342.7M
total assets, end of FY2025
Total assetsUSD 342.7M
EquityUSD 256.5M
CashUSD 166.1M
Gross debtUSD 18.0M
Net debtUSD -148.2M
Current ratio4.32×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.4
0.3
0.3
0.3
0.2
0.2
0.3
0.4
0.3
0.2
0.2
0.1
0.1
0.0
0.0
0.0
Operating income $B
0.1
0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.1
0.1
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.1
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.1
−0.0
−0.0
−0.0
−0.0
−0.0
0.1
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.32
0.28
0.37
−0.33
−0.15
−0.77
−0.24
−0.28
0.56
0.00
0.26
0.05
−0.04
−0.09
−0.14
−0.19
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
21.6
25.3
93.4
·
·
−287.8
−60.9
−48.6
106.2
0.9
47.5
7.6
−8.8
−48.0
−113.3
−187.2
Shares out B
0.15
0.15
0.15
0.11
0.11
0.11
0.11
0.11
0.11
0.11
0.11
0.11
0.10
0.09
0.07
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed